Detection of a novel panel of 24 genes with high frequencies of mutation in gastric cancer based on next-generation sequencing

Table 4 Treatment options based on gene mutations according to the OncokB database

Gene	Variation type	Variable area	Associated drug	Level of evidence
ERBB2	CNV	Amplification	Trastuzumab, Pembrolizumab	1
NF1	Mutation	Oncogenic variants	Trametinib, Cobimetinib	4
PIK3CA	Mutation	C420R, E542, E545, Q546, H1047	Alpelisib + Fulvestrant	3B
BRCA2	Mutation	Oncogenic variants	Olaparib, Talazoparib, Niraparib, Rucaparib	3B
FGFR2	Fusions/Mutation	Fusions, Oncogenic variants	Infigratinib, Erdafitinib, Debio1347, AZD4547	4
PTEN	Mutation	Oncogenic variants	GSK2636771, AZD8186	4
MET	CNV, exon 14-skipping	Exon 14-skipping, Amplification	Crizotinib	4
KRAS	Mutation/CNV	G12C, Oncogenic Mutations	Adagrasib, Sotorasib, Trametinb, Cobimetinib, Binimetinib	3B, 4
KIT	Mutation/CNV	Exon 8, 9, 11, 13, 14, 17, 18	Imatinib, Sunitinib, Regorafenib	4
MTOR	Mutation	Oncogenic variants	Everolimus, Temsirolimus	4
CDKN2A	Mutation	Oncogenic variants	Palbociclib, Ribociclib, Abemaciclib	4
PDGFRA	Mutation/CNV	Exon 12, 14, 18	Imatinib, Sunitinib, Regorafenib	4